New SARS-CoV-2 lineage reaches Singapore and seven other countries as researchers monitor mutations.
A newly identified COVID-19 lineage known as PJ.2.1 is drawing attention after being detected across North America, Europe, Asia, and Oceania. Early research suggests the variant carries numerous spike-protein mutations, but there is currently insufficient evidence that it causes more severe disease.
PJ.2.1 First Detected in Canada
PJ.2.1 was first identified in a sample collected in Ontario, Canada, on May 2, 2026. It was subsequently reported in other Canadian provinces, including Alberta, British Columbia, and New Brunswick. Researchers describe it as a saltation variant, characterized by an unusually large cluster of genetic changes emerging over a relatively short period.
Variant Reaches Eight Countries
As of the reporting period, PJ.2.1 had been detected in at least eight countries: Canada, the United States, France, Spain, Singapore, Australia, New Zealand, and Israel. The earliest reported US detection was in New York City on June 30, 2026, followed by detections in several other states. Researchers also reported indications of sustained local transmission in parts of Spain.
Ontario Sequencing Shows Rising Share
According to Public Health Ontario data cited by detikHealth, PJ.2.1 accounted for 25.2% of sequenced SARS-CoV-2 samples between September 20 and October 17, 2026. That represented an increase of 16.9 percentage points from the preceding four-week period, indicating that the lineage was becoming more common among sequenced samples in Ontario.
Mutations May Improve ACE2 Binding
Research published in the Journal of Infection found that PJ.2.1 carries numerous mutations in its spike protein, which SARS-CoV-2 uses to enter human cells. Laboratory experiments suggest that increased binding to the ACE2 receptor, rather than substantially greater antibody evasion, may help explain the variant’s spread. Blood samples from people vaccinated with an LP.8.1-adapted COVID-19 vaccine retained the ability to neutralize PJ.2.1 in laboratory tests, although the findings do not establish the vaccine’s real-world effectiveness against infection or severe disease caused by the lineage.
No Evidence Yet of More Severe Disease
Researchers have not established that PJ.2.1 causes more severe illness, higher hospitalization rates, or more deaths than other circulating variants. No unique symptoms have been identified, with reported COVID-19 symptoms continuing to include fever, cough, sore throat, congestion, headaches, muscle aches, and fatigue. Because these symptoms can resemble influenza and other respiratory infections, diagnostic testing remains necessary to identify the cause.
PJ.2.1’s detection across eight countries shows why genomic surveillance remains important as SARS-CoV-2 continues to evolve. For Singaporeans, its local detection makes continued monitoring particularly relevant, while current evidence does not establish greater disease severity. For Indonesians, developments in nearby Singapore and other countries provide useful regional context as health authorities and researchers continue assessing the variant’s behavior.
Keywords: COVID-19 PJ.2.1, New COVID Variant, Singapore COVID Variant, SARS-CoV-2 Variant, PJ.2.1 Spread, COVID Surveillance
